The role of CDK4/6 inhibitors in early breast cancer by Gil Gil, Miguel et al.
lable at ScienceDirect
The Breast 58 (2021) 160e169Contents lists avaiThe Breast
journal homepage: www.elsevier .com/brstThe role of CDK4/6 inhibitors in early breast cancer
Miguel Gil-Gil a, Emilio Alba b, Joaquín Gavila c, Juan de la Haba-Rodríguez d,
Eva Ciruelos e, Pablo Tolosa e, Daniele Candini f, Antonio Llombart-Cussac g, h, *
a Institut Catala d'Oncologia IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
b Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Victoria, Malaga, Spain
c Fundacion Instituto Valenciano de Oncología, Valencia, Spain
d Department of Medical Oncology, Hospital Universitario Reina Sofía, Instituto de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba, Spain
e Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
f Medical Department, Pfizer Oncology, Madrid, Spain
g Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain
h FISABIO, Universidad Catolica de Valencia, Spaina r t i c l e i n f o
Article history:
Received 8 February 2021
Received in revised form
21 May 2021
Accepted 21 May 2021
Available online 25 May 2021
Keywords:
Early breast cancer
Cyclin-dependent kinase 4/6 inhibitors
Adjuvant therapy
Palbociclib
Abemaciclib* Corresponding author. Department of Medical O
Vilanova, Calle de Sant Clement 12, 46015 Valencia, S
E-mail address: allombart1@yahoo.com (A. Llomb
https://doi.org/10.1016/j.breast.2021.05.008
0960-9776/© 2021 Published by Elsevier Ltd. This isa b s t r a c t
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the
treatment of advanced hormone receptor-positive (HRþ) and human epidermal growth factor receptor 2-
negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of
early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/
6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the
results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent
results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the
combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that
we have so far and future directions of the role of these drugs in the treatment of early BC.
© 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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an open access article under the C1. Introduction
Breast cancer (BC) is the most common invasive cancer in
women. In developed countries, more than 90% of patients are
diagnosed in an early-stage [1]. Approximately two-third of BC





CCCA Complete cell cycle arrest




EMA European Medicines Agency
ET Endocrine therapy
FDA Food and Drug Administration
FU Follow up
HER2e Human epidermal growth factor receptor 2-negative
HRþ Hormone receptor-positive
IDFS Invasive disease-free survival
IMC Independent monitor committee
LHRH Luteinizing hormone releasing hormone
NCT Neoadjuvant chemotherapy
NET Neoadjuvant endocrine therapy
ORR Objective response rate
OS Overall survival
pCR Pathological complete response
PEPI Preoperative endocrine prognostic index
PFS Progression-free survival
pRb Retinoblastoma protein
RCB Residual cancer burden
ROR Risk of recurrence
RT Radiation therapy
SAE Serious adverse event
SERDs Selective estrogen receptor degraders
SOC Standard of care
TK1 Thymidine kinase 1
VTE Vascular thrombo-embolic
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growth factor-2 receptor overexpression (HER2e) [2]. Despite
available treatments for early HRþ/HER2e BC, up to 20% of patients
will relapse within 10 years from diagnosis [3], and the likelihood
rises in patients harboring genomic or clinical risk factors [4,5]. In
recent years, novel therapies have been explored with the aim of
minimizing the risk of distant relapse in patients with early HRþ/
HER2e BC.
The cyclin-dependent kinases that regulate cell-cycle progres-
sion are involved in the development of resistance to endocrine
therapy (ET), and therefore have been considered as promising
targets for BC therapy [6,7]. The incorporation of cyclin-dependent
kinases 4/6 inhibitors (CDK4/6i) into the treatment of HRþ/HER2e
advanced BC was the main advance in decades, providing consis-
tent benefits in progression-free survival (PFS), objective response
rate (ORR), overall survival (OS) and quality of life [8]. Palbociclib
was the first highly-selective oral CDK4/6i showing substantial PFS
gains when combined with aromatase inhibitors (AI) or fulvestrant
in both endocrine sensitive or resistant HRþ/HER2- advanced BC
patients [9]. Palbociclib, as well as abemaciclib and ribociclib, two
other CDK4/6i, received Food and Drug Administration (FDA) and
European Medicines Agency (EMA) approval for the treatment of
HRþ/HER2e advanced BC in combination with either AI or fulves-
trant based on the pivotal PALOMA, MONARCH and MONALEESA
registration programs that included a total of 8 randomized clinical
trials [10e16]. Following on this success, a robust program of
clinical research was developed to incorporate CDK4/6i for the
treatment of HRþ/HER2e early BC, including window-of-
opportunity, neoadjuvant and adjuvant strategies.
In this article we review the status of all studies with CDK4/6i
associated with ET for the treatment of early BC, and especially
those with published data. Since patient selection is critical for the
application of these therapies, we also review our current under-
standing on biomarkers related to CDK4/6i and prognostic factors
in the recruited populations and we offer some ideas about the
possible interaction between CDK4/6i and radiotherapy (RT).
Finally, we discuss the possible causes of conflicting results be-
tween studies and we make a reasoned and constructive critical
assessment of the influence that trial designs may have had on the
outcomes.1612. CDK4/6 inhibitors as neoadjuvant therapy for early BC
Neoadjuvant endocrine therapy (NET) was not broadly accepted
until recently as an appropriate standard of care (SOC) in early BC.
NET was mostly reserved for elderly patients or the ones carrying
significant comorbidities. This decision was related to the molec-
ular heterogeneity of HRþ/HER2e BC, and the lack of validated
predictive and/or prognostic markers that could properly allocate
patients to NET or neoadjuvant chemotherapy (NCT). However,
nowadays the interest and use of NET in clinical practice is growing,
especially for patients presenting tumors with high hormone re-
ceptor expression and low proliferative markers. The incorporation
of CDK4/6i to NET, based on their described efficacy in metastatic
disease, could accelerate these changes.
To date, the studies published on CDK4/6i as neoadjuvant
treatment can be classified into two main groups (Table 1). Those
which compared CDK4/6i þ ET versus ET alone, and those that
compared CDK4/6i þ ET versus standard chemotherapy (CT). Most
of them were randomized phase 2 studies and some of them
focused on early or delayed biologic endpoints, such as changes on
the proliferative marker Ki67 as a measure of complete cell cycle
arrest (CCCA) or exploring potential markers of early or late resis-
tance to ET and CDK4/6i. These include MONALEESA-1 and FELINE
for ribociclib [17,18], PALLET for palbociclib [19], and NeoMONARCH
for abemaciclib [20]. The decrease in Ki67 staining at 2e4 weeks
from the start of NET is a robust and validated marker of efficacy
[21]. CDK4/6i combinations showed the highest antiproliferative
capacity in terms of CCCA rates defined as percentage of tumors
with Ki67 values <2.7% confirmed at an early point as well as at
surgery. However, the addition of a CDK4/6i induced no changes in
the proportion of preoperative endocrine prognostic index (PEPI)
score 0 or pathological complete response (pCR) at the time of
surgery. Currently, none of the trials have reported results on
event-free survival (EFS). Two important insights for future
research derived from these studies, and especially from Neo-
PalAna: first, a group of patients (approximately 25%), did
extremely well with ET alone; a second group clearly benefited
from the addition of CDK4/6i, probably by reversing primary re-
sistances to ET (60% of the total), and, finally, for a small proportion
of patients the tumor showed to be resistant to both interventions
[22]. A second aspect relates to the rebound effect observed on Ki67
values when the CDK4/6i is stopped: this effect may be particularly
relevant for palbociclib and ribociclib as both requires a one week
Table 1
Randomized studies with CDK4/6 inhibitors plus ET in neoadjuvant therapy.
Reference PALLET [19] NeoPAL [24] NeoPalAna [22] FELINE [18] CORALLEEN [25] MONALEESA-1 [17] NeoMONARCH [20]
Drug Palbociclib




125 mg qd 3 wks
on/1 wk
off þ letrozole
Anastrozole 1 mg/d 4 wks (cycle 0; with goserelin if
premenopausal), then palbociclib (125 mg/d on days 1
e21) on cycle 1 day 1 for four 28-day cycles unless
Ki67 >10% at day 15
Ribociclib 600 mg qd





3 wks on/1 wk
off þ letrozole
Ribociclib 400 mg/d 3 wks
on/1 wk off or Ribociclib
600 mg/d 3 wks on/1 wk
off þ letrozole
Abemaciclib 150 mg c/12 bd
continuously þ anastrozole





Arm 1: PIK3CA wild type cohort
Arm 2: Mutant PIK3CA cohort







Phase 2 randomized: Ana vs
Abema vs Ana þ Abema x 14







HRþ/HER2e early BC ERþ>66%/HER2e early
BC  2 cm
Postmenopausal
HRþ/HER2e
early BC  2 cm
Postmenopausal
HRþ/HER2e early BC HRþ/HER2e early BC  1 cm
Postmenopausal
N of patients 307 106 50 120 106 14 173
Control arm Letrozole 2.5 mg FEC x3 þ
Docetaxel x3
Letrozole
2.5 mg þ Placebo
AC x4 þ w
paclitaxel x12
Letrozole Anastrozole 1 mg
Key inclusion criteria Stage II y III Stage II y III
luminal by
PAM50
Stage II/III Stage II y III Stage I-IIIA
Luminal B by
PAM50
T >1 cm Grade 2-3 Stage I-IIIB
1st endpoint Change in Ki-67
CR
RCB 0-I CCCA day 15 PEPI score 0 % ROR low risk Rate of Ki-67 decrease CCCA day 14









PK, safety and genetic
profiling
CR; RR, pCR safety and Genes
changes
CDK4/6i exposure 14 weeks 19 weeks 24 weeks 24 weeks 2 weeks 14e16 weeks
Ki-67 Median log-fold
change (4,1
vs 2.2 p <0.001




CCCA at surgery (63.3% vs
75.7% vs 66.7% p ¼ 0.42
CCCA on D14 (51.7% vs
97.1% vs 57.2%
p ¼ 0.0001)
>10% on D14 (17.2% vs
2.8% vs 5.13% p ¼ 0.025
69% letrozole alone
96% Ribociclib
400 mg þ letrozole
92% Ribociclib
600 mg þ letrozole




54.3% vs 49.5% 74.5% vs 76% 80% (68%e90%)
41% (25%e58%)
52% (35%e68%)
71.4 vs 73.5 vs 77.8%
p ¼ 0.63
30.4% vs 50% vs 38.5%
p ¼ 0.25





pCR 3.3% vs 1.1%
p ¼ 0.43
e CCCA rate 87% vs. 26%, p <0.001 e 2% vs 5.8% e 4%
RCB 0e1 e 7.6% vs 15.7% e 6.1% vs 11.8% e e
PEPI score 0 e 17.3% vs 8% 25.8% vs 29.7 vs 20.6%
p ¼ 0.96
22.4% vs 17.3% e e
AEs (CDK4/6 i vs
control)
Any (99% vs 91%)
G3 (50% vs 17%)
G4 (4% vs 0%)
G3 43.4 vs 18.9%
G4 1.9% vs 20.7%
AST/ALT G3 2.7% vs 31% vs
17%





Febrile N 1% vs
13%
G3/4 ALT 20% vs
10%
G3/4 0% in all arms Any 96%
G3 36%
G4 2%












AC, Adriamycin plus Cyclophosphamide; AEs, Adverse Events; BC, Breast Cancer; CCCA, Complete Cell-Cycle Arrest; CDK4/6, Cyclin-Dependent Kinases 4 or 6; CR, Clinical Response; HR, Hormone Receptor; MRI, Magnetic
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effect can be reversed by prolonged treatment with CDK4/6i, sug-
gesting that extended exposure to these drugs could be needed to
maintain their cytostatic effect [23].
A second approach compared CDK4/6i þ NET with optimal CT
schemes. These studies were NeoPAL for palbociclib [24], and
CORALLEEN for ribociclib [25]. In these studies, the initial selection
of patients focused on high-risk BC based on genomic platforms
such as PAM50 risk of recurrence (ROR). Both studies showed that
NCT is associated with a higher activity in terms of cell death and
residual cancer burden (RCB) at the time of surgery, while CDK4/
6i þ NET showed a higher and faster antiproliferative effect based
on Ki67 changes.
To confirm CDK4/6i þ NET as a valid strategy, guidelines that
define which patients can benefit and the optimal duration of
treatment must be established. In this respect, the utility of
genomic platforms needs to be validated with studies of extended
follow-up. In coming years, we will have the results of studies with
new designs and strategies, such as the combination with new
selective estrogen receptor degraders (SERDs) and palbociclib
(NCT04436744) or the search for new predictive and prognostic
markers. The DxCARTES study (NCT03819010) will assess the role
of Oncotype DX Recurrence Score by measurement of molecular
changes before and after 6 months of palbociclib and NET [26]. The
CARABELA clinical trial (NCT04293393) investigates the role of 12-
month treatment with abemaciclib and NET versus NCT based on
anthracyclines and taxanes. Finally, whether letrozole and palbo-
ciclib before surgery offer a clinical benefit in patients with clinical
residual disease after completing NCT is being explored in the
PROMETEO II study (NCT04130152).
3. CDK4/6 inhibitors in adjuvant therapy for early BC
Four major trials have explored the role of CDK4/6i in the
adjuvant setting. Three of them, PALLAS and PENELOPE-B for pal-
bociclib, and MONARCH-E for abemaciclib have recently presented
results from their interim or final analyses [27e30]. NATALEE
(NCT03701334) for ribociclib is still ongoing [31].
PALLAS, MONARCH-E and NATALEE are 3 large, multicenter,
randomized, open-label Phase III trials evaluating the efficacy in
terms of invasive disease free survival (IDFS), of the addition of 2
years palbociclib, 2 years abemaciclib and 3 years ribociclib to
standard adjuvant ET (Table 2).
The PALLAS study included pre- and postmenopausal women or
menwith stage II (stage IIA limited to a maximum of 1000 patients)
or stage III early invasive BC [27]. A total of 5760 patients were
recruited from September 2015 to November 2018. Patients were
stratified according to stage, CT, age, and geographic region.
The MONARCH-E trial included pre- and postmenopausal
women or men with high-risk early invasive breast cancer, defined
as the presence of pathologic lymph node involvement and at least
one of the following factors indicating a higher risk of recurrence: 4
or more positive axillary lymph nodes, tumor size of at least 5 cm,
histologic grade 3, centrally tested Ki67 20% on untreated breast
tissue. A total of 5637 patients were included in the trial, from July
2017 to August 2019 and stratified for prior CT, menopausal status
and region [32].
The NATALEE trial is currently recruiting patients and the esti-
mated sample size is around 5000 of pre- and postmenopausal
women or men with anatomic stage II or III HRþ/HER2e early BC.
Stage II was defined as N1 or N0 (T2-3, N0) with G2-3 and/or
Ki67 20% (testing for Ki67 not mandatory), excluding G1 [31].
The PENELOPE-B trial included 1250 patients with HRþ/HER2e
early BC with residual disease after NCT and considered at high risk
by the clinical-pathological stage-estrogen/grade (CPS-EG score),163defined as CPS-EG score of3, or score 2 if nodal status at surgery is
ypNþ. Patients were randomized between February 2014 and
December 2017 to receive 13 cycles (approximately 1 year) of pal-
bociclib in combination with standard ET vs standard adjuvant ET
alone and were stratified by nodal status at surgery, age at first
diagnosis, centrally measured Ki67, global region of participating
sites, and risk status [30].
In the PALLAS study, after a median follow-up (FU) of 23.7
months, palbociclib failed to demonstrate a statistically significant
benefit in IDFS, with the IDFS rate at 3 years of 88.2% (palbociclib
arm) vs 88.5% (control arm) with a HR ¼ 0.93; 95% CI, 0.76e1.15
(p ¼ 0.51) [27]. However, in the MONARCH-E study, after a median
FU of 15.5 months, abemaciclib demonstrated to significantly
reduce the risk of recurrence, with an absolute difference of 3.5% in
the IDFS rate at 2 years being 92.2% (abemaciclib arm) vs 88.7%
(control arm) with a HR¼ 0.75; 95% CI, 0.60e0.93 (p¼ 0.01) [29]. In
the PENELOPE-B trial, at the time of final analysis, after a median FU
of 42.8 months, 308 IDFS events had occurred and the study did not
meet its primary endpoint: the addition of 1 year-palbociclib to SOC
adjuvant therapy in women with HRþ/HER2- BC at high risk of
relapse after NCT did not improve IDFS (HR ¼ 0.93, 95% CI [0.74,
1.16]; p ¼ 0.525) [30].
Other studies exploring palbociclib in the context of early BC are
still on-going. Two examples are the phase III POLAR trial
(NCT03820830) that is investigating the addition of 3 years of
treatment with palbociclib to standard endocrine therapy in iso-
lated loco-regional recurrence of early BC, and the phase II
APPALACHES randomized trial (NCT03609047) evaluating adjuvant
treatment with 2 years of palbociclib in combination to standard ET
as an alternative to CT in elderly patients (age 70 years) with
clinical high-risk HRþ/HER2- early BC.
In addition to these studies, some noteworthy on-going trials
are also exploring CDK4/6i in settings which take into consider-
ation data derived from genomic platforms. For example, the phase
III ADAPTcycle (NCT04055493), now recruiting, will evaluate the
role of ribociclib (600 mg) in combinationwith ET compared to SOC
CT (followed by adjuvant ET) in patients with intermediate genomic
risk as defined by Oncotype®. Similar design can be found in the
phase III ADAPTlate (NCT04565054), where a population defined as
high-risk of relapse by Oncotype® and that received SOC CT is now
randomized to receive either abemaciclib þ ET or ET alone.
It is also worth highlighting the phase 2 HIPEx study
(NCT04247633), a Korean phase II, multi-center, single-arm trial
that evaluates the efficacy of palbociclib with ET as adjuvant
treatment in patients with clinical and genomic high risk (defined
by The Breast Cancer Test [BCT] platform) HRþ/HER2- T1-2 N0-1
early BC.
Follow-up has been adapted with new techniques, such as
circulating tumor DNA (ctDNA), which can detect molecular re-
lapses. Examples of this innovative design are the phase II LEADER
(NCT03285412) with ribociclib or the recently opened phase II
DARE (NCT04567420) with palbociclib. PALLAS, MONARCH E and
NATALEE have a translational research program that will analyze
ctDNA and tissue samples, and the results will be published in
coming years.
4. Predictors of efficacy and resistance to CDK4/6 inhibitors
Defining biological predictive markers would be highly valuable
in the selection of patients to be treated with CDK4/6i in early BC.
Common clinical and pathological criteria have been explored in
early and advanced disease, with no relevant findings
[11,20,33e40]. Similarly, the benefit of CDK4/6i is independent of
the luminal subtype [22,33,41]. In fact, mechanisms of resistance
are complex and still poorly understood in terms of underlying
Table 2
Phase 3 studies with CDK4/6 inhibitors plus ET in adjuvant therapy.
PALLAS [27] MONARCH-E [29] PENELOPE-B [30] NATALEE [31]
Drug Palbociclib 125 mg qd, 3 wks on/1 wk
off
Abemaciclib 150 mg c/12 bd
continuously
Palbociclib 125 mg qd 3 wks on/1 wk
off
Ribociclib 400 mg qd 3 wks
on/1 wk off
Study design Phase 3 randomized, not placebo-
controlled
Phase 3 randomized, not placebo-
controlled
Phase 3 randomized, placebo-
controlled
Phase 3 randomized, not
placebo-controlled
Population HRþ/HER2e early BC HRþ/HER2e early BC HRþ/HER2e early BC, high risk after
neoadjuvant CT
HRþ/HER2e early BC
Number of patients 5760 5637 1250 Estimated 5000
Patients  N2 or N1 if
G3 or T3/4
58.7% 100% (includes Ki67  20% in N1) 50.4% e
Start Date/LPFV September 2015eNovember 2018 July 2017eAugust 2019 February 2014eDecember 2017 December 2018/Ongoing
Patients with prior CT 82.4e82.7% 95.3e95.5% 100% e
Key inclusion criteria Stage II y III 4 or more positive lymph nodes
1-3 lymph nodes and also T  5 cm,
G3, or Ki67 20
RID post-neoadjuvant CT. CPS-EG
score 3, or score 2 if nodal status at
surgery is ypNþ
Stage II (if N1 or N0 (T2-3, N0)
with G2-3 and/or Ki67 20%)
or stage III
Primary endpoint IDFS IDFS IDFS IDFS
Secondary endpoints DRFS, LRRFS, OS and safety DRFS, OS, safety, PK and PROs IDFS excluding second non-BC, DRFS,
OS, IDFS by molecular subtype, safety,
PK and QoLQ
RFS, DDFS, OS, PROs, PK, safety
and tolerability
CDK4/6i exposure 2 years 2 years 1 year 3 years
Median Follow Up 23.7 months 15.5 months 42.8 months e
IDFS events 351 events; 170 (palbociclib) vs 181
(control), p ¼ 0.51
323 events; 136 (abemaciclib) vs 187
(control), p ¼ 0.026
308 events; 152 (palbociclib) vs 156
(control), p ¼ 0.525
e
IDFS rate 88.25% (palbociclib) vs 88.5% (control)
HR ¼ 0.93; 95% CI, 0.76e1.15
(p ¼ 0.51) at 3 years
92.2% (abemaciclib) vs 88.7%
(control) HR¼ 0.75; 95% CI, 0.60e093
(p ¼ 0.01) at 2 years
81.2% (palbociclib) vs 77.7% (control)
HR ¼ 0.93; 95% CI, 0.74e1.17
(p ¼ 0.525) at 3 years
e
DRFS rate 89.3% (palbociclib) vs 90.7% (control)
HR ¼ 1; 95% CI, 0.79e1.27
(p ¼ 0.9997)
93.6% (abemaciclib) vs 90.3%
(control) HR¼ 0.72; 95% CI 0.56e0.96
(p ¼ 0.01)
e e





Any grade (99.4% vs 88.6%)
G3 (66.8% vs 13.8%)
G4 (5.6% vs 0.8%)
Any grade (97.9% vs 86.1%)
G3 (43.0% vs 12.0%)
G4 (2.5% vs 0.7%)
Any grade (99.8% vs 99.8%)
Hematological G3/4 (73.1% vs 1.3%)
Non-hematological G3/4 (19.9% vs
19.5%)
e






27.1% (discontinuation due to AEs)
42.7% (dose reduction)
27.7% (discontinuation)
17.2% (discontinuation due to AEs)
47.6% (dose reduction)
20% (discontinuation)
5% (discontinuation due to AEs)
e
SAEs 12.4% vs 7.6% 12.3% vs 7.2% 9.3% vs 8.7%
CDK4/6i relevant
toxicity
G3-4 neutropenia, 61.3% Any VTE 2.3% (1.2% G 3e4) and any
ILD 2.7% (0.3% G3e4)
e e
AEs, Adverse Events; BC, Breast Cancer; CDK4/6i, Cyclin-Dependent Kinases 4 or 6 inhibitors; CI, Confidence Interval; LPFV, last patient first visit; CPS-EG, Clinical-Pathologic
Stage - Estrogen/Grade; CT, chemotherapy; DRFS, Distant Relapse-Free Survival; HR, Hormone Receptor; IDFS, invasive Disease-Free Survival; ILD, Interstitial Lung Disease;
LRRFS, Loco-Regional Recurrences-Free Survival; OS, Overall Survival; PK, pharmacokinetics; PROs, Patients Reported Outcomes; QoLQ, Quality of Life Questionnaire; RID,
Residual Invasive Disease; VTE, Venous Thromboembolic Event; wk, week; SAEs, Serious Adverse Events.
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samples from the large phase-III studies in advanced disease: most
of them analyzing metastatic, endocrine pretreated tumors,
limiting their value in early disease.
PIK3CA and ESR1, two of the most prevalent mutated genes in
metastatic HRþ/HER2- BC, did not significantly affect the response
to CDK4/6i treatment in the metastatic stage [13,14,42]. PIK3CA
mutations in neoadjuvant studies did not significantly affect pro-
liferation changes [20,22].
The retinoblastoma gene (RB) is central to the mechanism of
action of CDK4/6i. Preclinical models have shown that the absence
of a functional RB1 acts as a mechanism of resistance to CDK4/6i. In
a retrospective study on 348 patients with advanced HRþ/HER2- BC
treated with CDK4/6i plus ET, patients with baseline loss of RB1
showed a PFS of 3.6 months compared with 10.1 months of those
with functional RB1 (p ¼ 0.0004). However, only 2.5% of the sam-
ples presented alterations in RB1 [43]. In a pooled analysis of
MONALEESA-2, -3, and -7, evaluating the baseline ctDNA of 1503
patients, patients with wild-type RB1 had a numerically longer PFS
with ribociclib compared to the mutant RB1 patients (1.7% of all
tumors) [44]. Neoadjuvant studies confirm the low prevalence of
basal mutant RB1 as well as tumors with low RB1 expression, but164also suggest that the loss of RB1 activity induces primary resistance
to CDK4/6 [20,22].
A whole exome sequencing of 59 tumor samples from CDK4/6i
treated patients focused on alterations enriched in the resistant
versus sensitive tumors. The biallelic disruption of RB1 as well as
activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2
were identified [45]. In vitro experiments confirmed that these al-
terations conferred CDK4/6i resistance.
In the PALOMA-3 study, baseline TP53mutations on ctDNAwere
significantly associated with shorter PFS, as were baseline FGFR1
amplification, identifying patients at risk of early progression [46].
Similarly, ctDNA from patients enrolled in MONALEESA-2 showed
that those with FGFR1 amplification (5% of all patients) exhibited a
shorter PFS compared to patients with FGFR1 wild-type tumors
[47]. In contrast, a benefit of ribociclib was observed independently
of the alterations of TP53 and FGFR1 found in the baseline ctDNA in
MONALEESA-3 [48]. The MONALEESA-2 study also demonstrated
that ribociclib prolonged PFS regardless of TP53 mutational status
[49].
Proteins involved in the CDK4/6 signaling cascade have been
analyzed. In a preclinical study, phosphorylated CDK4was detected
in all palbociclib-sensitive cell lines and was not detected in any of
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2 studies failed to demonstrate a relationship between baseline
gene expression levels of CCND1, CCNE1/2, CDK2/6 and CDKN2A and
benefit with the addition of palbociclib to letrozole treatment [33].
Increased CDK6 activity has been implicated in de novo and
acquired resistance to CDK4/6i in several preclinical studies with
palbociclib, ribociclib, and abemaciclib [36,37,40]. However, the
clinical validation of cyclin D-CDK4/6 complex as a predictive
biomarker has failed in most pivotal studies [11,46,49]. FAT1 loss
increases CDK6 levels in vitro and in vivo. This is mediated by the
accumulation of YAP and TAZ transcription factors (key effectors of
the Hippo pathway) on the CDK6 promoter. Indeed, genomic al-
terations of the Hippo pathway components have been found to
promote CDK4/6i resistance [43].
Preclinical data suggest that overexpression and amplification of
cyclin E1 is predictor of acquired CDK4/6i resistance [50]. In
PALOMA-3, CCNE1 was shown to be highly predictive when eval-
uated in metastatic biopsies, but only marginal in simple primary
biopsies [41]. But in the MONALEESA-3 and PALOMA-2 studies, a
similar benefit was observed regardless of levels of expression of
CCNE1 [33,51]. CCNE1 amplification was also an adverse predictor
in the NeoPalAna trial [52], and high CCNE1 mRNA expression was
associated with a worse prognosis in both MONALEESA-2 [36] and
in the preoperative phase II POP study [34]. Similarly, in the neo-
Monarch study, resistant tumors showed higher expression of
CCNE1 than sensitive tumors, although this was not statistically
significant [20]. These data would support the hypothesis that
CCNE1 could be a marker of resistance to CDK4/6i. The correlation
between CCNE1 and RB1 is still unclear. In the NeoPalAna, the
CCNE1/RB1 ratio discriminated better than CCNE1 or RB1 alone
between palbociclib sensitive and resistant patients [50].
Thymidine kinase-1 (TK1) plays a key role in DNA replication
and is regulated by the transcription factor E2F pathway. In Neo-
PalAna, TK1 was measured in plasma samples from patients
receiving palbociclib in monotherapy or palbociclib plus ET. While
baseline TK1 was not prognostic, after one month of treatment
patients with increased TK1 had a worse outcome compared to
those with decreased or stable activity. This represented the first
evidence to suggest that the dynamics of TK1 on CDK4/6i might
serve as an early marker of resistance [53].
In conclusion, although there have been some promising results,
the attempts to identify a subgroup of patients more likely to
benefit from CDK4/6i have been unsuccessful. More robust clinical
studies are needed to validate whether all those potential bio-
markers can discriminate early CDK4/6i sensitivity or resistance.
Vast translational research programs are underway in all three
adjuvant studies, including integration of molecular platforms, and
will undoubtedly contribute to the knowledge of the biology
behind CDK4/6i activity in early ERþ/HER2- BC.
5. Radiotherapy and CDK4/6 inhibitors
The combination of CDK4/6i and RT has been considered of risk
as it may exacerbate known CDK4/6i toxicities, particularly neu-
tropenia and leukopenia. However, pre-clinical data indicate that
CDK4/6i may enhance the therapeutic effects of RT [54,55]. Spe-
cifically, palbociclib may act as an inhibitor of double-stranded DNA
repair [56], and abemaciclib as a multi-functional radiation modi-
fier [57]. In pre-clinical models, CDK4/6 inhibition may exert a
protective effect on RT-induced gastrointestinal toxicity [58]. Pal-
bociclib may also have a radio-sensitizing effect by interacting with
the p53-ATM signaling axis [59].
In the context of metastatic BC, some series have analyzed the
possible association of palliative RT with concomitant CDK4/6i
regimens. With the bias from retrospective analyses, no potentially165harmful interactions were identified, nor increase in hematological,
skin, neurological or gastrointestinal toxicity were observed when
combining CDK4/6i and radiotherapy compared to CDK4/6i alone
[60e64]. The largest case series reported on concomitant or
sequential treatment with RT and CDK4/6i regimens included 85
patients with palbociclib or ribociclib, confirming that treatment
with RT palliative did not impact on CDK4/6 inhibitors dose
reduction or discontinuation due to exacerbation of adverse events
[64]. These results should be confirmed in larger, controlled studies
with greater FU to allow for extrapolation of these data in the
context of early BC, where RT doses are higher, and toxicities could
be exacerbated in a different way.
Unfortunately, a great number of questions remains unsolved
regarding RT and CDK4/6i interactions in early BC. All principal
trials in early BC allowed concomitant treatment with CDK4/6i and
RT, but the timelines between the end of RT and the start of adju-
vant treatment varied among studies. Patients with prior CT re-
ported higher hematological toxicities on PALLAS, but no report has
been presented for prior RT. Could RT have played a role in the
discontinuations of CDK4/6i observed in these randomized trials?
More questions are opened and more clinical trials with a
concomitant or sequential use of adjuvant RT and CDK4/6i are
required to better understand if this combination is feasible and
whether there is a synergism between CDK4/6i and RT to be
explored. Relevant examples of on-going studies are presented in
Table 3.
6. Discussion and conclusions
Based on survival gains and outstanding tolerability, the CDK4/
6i have become the new SOC for patients with advanced HRþ/
HER2e BC. Vast research programs have been undertaken to
translate benefits to early-stage BC patients. Studies in the neo-
adjuvant setting had provided consistent safety and efficacy results.
However, in line with studies of the advanced disease, no reliable
predictive biomarker has been identified to guide patient selection.
The first-generation CDK4/6i adjuvant trials selected patients
harboring “classical” prognostic high-risk clinic-pathological char-
acteristics. Results from PALLAS, PENELOPE-B and MONARCH-E
trials have been recently published [27,29,30,32], generating
considerable debate. The three trials, with IDFS as primary objec-
tive, provided diverging results. PALLAS at a median FU of 23.7
months showed that the addition of 2 years of palbociclib to SOC
adjuvant ET provided no IDFS benefits (HR ¼ 0.93, p ¼ 0.51).
PENELOPE-B, at a median FU of 42.83 months, also offered no sig-
nificant benefit from the addition of one year 13 months of pal-
bociclib to ET (HR¼ 0.93, p¼ 0.53). In contrast, MONARCH-E, with a
median FU of 15.5 months reported a statistically significant benefit
with 2 years of abemaciclib þ SOC adjuvant ET (HR ¼ 0.75;
p ¼ 0.0092).
The three studies presented relevant differences, particularly in
the definition of high-risk patients and the uses of previous CT.
PENELOPE-B required residual invasive disease at surgery following
adequate neoadjuvant CT. MONARCH-E required node-positive
disease, and one additional risk factor for N1, histologic grade 3,
Ki-67 20%, or tumor size 5 cm. PALLAS study included stage
IIeIII HRþ/HER2- BC patients, and up to 13% were node-negative.
Previous use of CT was quite different, 100% in PENELOPE-B, 95%
in MONARCH-E and 83% in PALLAS. The three studies had a median
age population of 50e52 years; however, the use of luteinizing
hormone releasing hormone (LHRH) agonists was in the range of
20% in all 3 studies. The better prognosis suggested for patients in
PALLAS was also supported by the indirect comparison of the
control arms; at 2-years the IDFS was 84% in PENELOPE-B, 89% in
MONARCH-E, and in the range of 93% for PALLAS.
Table 3
On-going clinical trials in breast cancer with CDK4/6i in combination with RT.
Study name NCT Phase n Status Type of RT Arm Primary
Outcome
ASPIRE NCT03691493 II 42 Recruiting Palliative RT at bone metastases Palbociclib þ ET þ RT Response rate
PALATINE NCT03870919 NA 200 Recruiting Locoregional RT in de novo Stage IV Palbociclib þ Letrozole þ locoregional
treatment (Cx ± RT or RT)
OS
SRS with CDK4/6i in brain
metastases




NCT04563507 II 102 Not yet
recruiting
SBRT (50 Gy in 5 fractions) to each
metastatic lesion
Palbociclib þ Letrozole þ RT PFS
NCT, number of clinical trial; RT, radiation therapy; ET, endocrine therapy; NA, not applicable; OS, overall survival; SRS, stereotactic radiosurgery; CDK4/6i, Cyclin-Dependent
Kinases 4 or 6 inhibitors; CNS, central nervous system; ERþ, positive for endocrine receptors; SBRT, stereotactic body radiation therapy; Gy, Gray; PFS, progression-free
survival.
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factor to be analyzed. In the PALLAS study, 42% of patients stopped
palbociclib prematurely; and 27% of them due to an adverse event,
mainly grade 3 neutropenia [65]. The PALOMA-2 trial in the first-
line advanced BC setting, patients faced a similar palbociclib
regimen and schedule, and the discontinuation rate was as low as
9% [9,10,13]. However toxicities and severe adverse events reported
in PALLAS were similar in kind and incidence to the PALOMA-2 and
PALOMA-3 [27]. The only difference between these trials is related
to the management of neutropenia, as repeated grade 3 asymp-
tomatic neutropenia required permanent treatment discontinua-
tion. In contrast, the CDK4/6i total discontinuation rate in
PENELOPE-B and MONARCH-E were much lower, 19.5% and 21.7%
respectively. However, in MONARCH-E discontinuation rates may
still increase, as the median FU was short (19.15 months) and many
patients were still under treatment [29,66]. Adherence to treat-
ment is of utmost importance in the efficacy of prolonged oral
therapies. The symptoms and side effects derived from the treat-
ment are the main causes for an early discontinuation of adjuvant
ET [67], and lack of adherence may be the cause of an increase in
the rate of recurrence and mortality [68,69]. When considering the
incorporation of CDK4/6i into adjuvant ET, the duration of treat-
ment and toxicity can be decisive in adherence and in the selection
between the different therapeutic options. It is possible that
symptomatic toxicities due to CDK4/6i, such as asthenia, diarrhea,
nausea, abdominal pain, arthralgias and alopecia, are likely to limit
adherence to treatment. When selecting the best therapeutic op-
tion, probably it would be advisable consider the dropout rates
from the ongoing studies, the toxicity profile of each CDK4/6i, and
the patient characteristics.
The toxicity profile of CDK4/6i in early stage was not dissimilar
to the previously reported in advanced disease, but the relevance
may be different. In the palbociclib trials, and excluding the well-
known neutropeniaeleukopenia effect, other severe events were
quite infrequent. In PALLAS, fatigue (2%), arthralgia (1%), or upper
respiratory tract infections (1%) were the most frequent grade 3
toxicities. The type and incidence of AEs in MONARCH-E were in
line to the ones reported in advanced BC. Diarrhea (7%), fatigue
(3%), and abdominal pain (1%) were the most common grade 3
toxicities for abemaciclib. However, the vascular thrombo-embolic
(VTE) disorders (2%) and particularly pulmonary embolism (1%),
although already reported in the metastatic scenario, should be
carefully analyzed. In fact, the incidence of pulmonary embolism
may be underestimated in MONARCH-E at this moment: FU is still
short, and many patients remain on treatment. Moreover, a higher
incidence of VTE was identified in the MONALEESA-7 trial for the
combination of ribociclib, LHRH-agonists, and tamoxifen in pre-
menopausal patients, so a third factor that needs to be explored is
the potential interaction with tamoxifen.
PALLAS and MONARCH-E achieved the predefined number of166IDFS events for interim analyses within 23.8 and 15.5 months of
median FU respectively. In summary, many events occurred within
the first two years of ET in both studies. International guidelines
categorize progressions within the first 2 years of adjuvant ET as
primary endocrine resistant, where endocrine sensitivity in
advanced disease is clearly compromised.With this very short FU in
MONARCH-E, abemaciclib somehowprevented endocrine-resistant
events. In the advanced setting indirect analysis suggest a different
activity profile for abemaciclib and the other two CDK4/6i.
Although non statistically significant, the OS gain in MONARCH-2
was relevant for patients with primary endocrine resistant
criteria (HR 0.69). PALOMA-3 OS analysis identified a benefit for
patients with endocrine sensitivity to the prior ET line (HR ¼ 0.7,
p ¼ 0.008) but not for non-sensitive patients (HR ¼ 1.1, p ¼ 0.29). A
meta-analysis of the MONARCH-2 and -3 trials showed that abe-
maciclib was more efficient among tumors with aggressive profiles,
including short disease-free interval, high grade, or high Ki-67 [70].
Does abemaciclib have underlying mechanisms that may
explain differences in early stages but not necessarily for advanced
disease? Neoadjuvant studies identified that the oneweek of CDK4/
6i rest is enough to observe an increase in cell proliferation
measured by Ki-67 [17e19,24,25,71]. This effect has not been seen
with abemaciclib as it does not require a one-week off between
cycles. It is unlikely that the small differences in the pharmacoki-
netics of the three drugs could explain this effect. All three CDK4/6i
have a similar absorption, distribution, and metabolization by
CYP3A4. Maximum concentration (Cmax) is achieved within hours
in all cases and the half-life within two days. Only for abemaciclib
the saturation of drug absorption supported a twice-daily dosing
regimen [72].
The three CDK4/6i display subtle differences in kinase selec-
tivity. Abemaciclib is about 14 times more potent inhibitor of CDK4
than of CDK6 and is also a potent inhibitor of CDK9. For ribociclib
and palbociclib the IC50 ratio between CDK4 and CDK6 ranges 1.6
to 0.4. As CDK4 is more prevalent in hematological cell lines, neu-
tropenia is the dose-limiting toxicity for both palbociclib and
ribociclib. Both drugs require aweek of rest between cycles to grant
full hematological recovery. Abemaciclib exerts less hematological
toxicity, and it does not require dose interruptions, being gastro-
intestinal the most common dose-limiting toxicity [73,74]. Pre-
clinical studies have shown that continuous administration of
abemaciclib reduced tumor growthmore efficiently compared with
an intermittent schedule [72]. Abemaciclib also induces high
senescence in BC cell lines. In fact, the continuous regimen for
abemaciclib may be crucial when treating micro-metastatic resid-
ual disease but not so relevant for controlling advanced disease
[73].
Will a longer FU reveal differences in both trials? If palbociclib
endorses activity in endocrine sensitive tumors, longer FU will be
required to show benefits. Indeed, trials comparing different
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differences in the first few years. The SOFT trial in high-risk pre-
menopausal patients required up to 8 years of median FU to
demonstrate that the addition of an LHRH agonist to tamoxifen
increased the recurrence-free survival (HR ¼ 0.76, p ¼ 0.009).
Similar observations can be addressed for the adjuvant studies of
aromatase inhibitors vs. tamoxifen in postmenopausal patients.
PALLAS was designed to capture information up to 10 years and
may identify late changes on the pattern of IDFS. Although results
will be jeopardized by the early trial interruption and the high
discontinuation rates.
The PENELOPE-B results, with 42.8 3-months follow-up, shed
new light on this debate. Although patients received just one year
of palbociclib (13 cycles), patients were definitively high-risk by
clinical-pathological criteria, and the discontinuation rates were
reasonable. Differences in IDFS were observed at two years (88.3%
vs 84.0% IDFS for palbociclib and placebo respectively), but the ef-
fect diluted over time, and at 4-years the IDFS rates were similar
(72.4% and 73.0% for palbociclib and placebo respectively). These
findings suggest that one-year treatment with palbociclib was able
to delay relapses but eventually not prevent them. The IDFS dif-
ferences at 2-years for the CDK4/6i in MONARCH-E and PENELOPE-
B are very similar (3.5% and 4.3% absolute differences respectively).
If the effect of CDK4/6i could vanish over time, more mature FU is
required from MONARCH-E to rule out this phenomenon.
The decision process defining prognosis and establishing
optimal systemic therapy in early ERþ/HER2- BC is a complex de-
cision. Two molecular platforms, MammaPrint and Oncotype-Dx,
have demonstrated to be efficient identifying the lack of benefit
from CT in node-negative and node-positive (up to 3 lymph-nodes)
and have become standard in clinical practice, but unfortunately
the MONARCH-E defined molecular risk by Ki-67 status. Future
studies should address the benefits of CDK4/6i in both high and low
risk patients by molecular platforms. Several ongoing studies will
help establish the value of the CDK4/6i in different early BC pop-
ulations. The ADAPTcycle is the first to explore ribociclib in patients
with genomic intermediate risk and the ADAPTlate is the first to
explore abemaciclib in patients with clinical or genomic high risk.
In conclusion, the three adjuvant CDK4/6i trials present relevant
differences on patient characteristics, CDK4/6i schedule, treatment
duration, and discontinuations rates that may have contributed to
the different trial outcomes. However, the activity of abemaciclib in
MONARCH-E is remarkable, with a significant 2-year IDFS rate
reduction that is mostly related to the prevention of distant re-
currences (93.6 vs 90.3%, HR ¼ 0.717, p ¼ 0.0085). Mature data are
needed to consolidate the early IDFS benefits observed in
MONARCH-E and establish the safety profile. Also, a late benefit of
palbociclib in more hormone-sensitive tumors cannot be ruled out.
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